BOURLA ALBERT 4

What Happened
Albert Bourla, Pfizer’s Chairman & CEO, was granted 25 derivative units (phantom shares) on 2026-06-30 at $24.08 per unit, a total value of $602. This was recorded on an SEC Form 4 filed 2026-07-01 and is reported as an award/grant (derivative), not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-30 — 25 units at $24.08 each (total $602).
• Transaction type: A (award/grant) — derivative units (phantom shares).
• Shares/units owned after transaction: Not disclosed in this filing.
• Filing date: 2026-07-01 (timely filing; within the Form 4 reporting window).
• Footnotes: F1 — each unit represents one phantom share of common stock. F2 — units were acquired under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan; they are cash-settled upon the reporting person’s separation from service and may be transferred into an alternative investment account at any time.

Context
These are phantom (cash-settled) units tied to Pfizer common stock, meaning they do not represent currently issued shares and are settled in cash later—so they do not convey voting rights or immediate stock ownership. Such deferred-compensation awards are common for executives and, given the small dollar value here, this transaction appears to be routine compensation rather than a market-confidence signal.